lilly glp 1 drug Novo, buoyed by fast-growing GLP-1 sales Lilly's Trulicity joins pay-for-performance trend
Description
Early biosimilar pipelines now coincide with once-weekly and dual-incretin innovations, encouraging payers to re-examine cost-effectiveness thresholds and to broaden indication coverage beyond glycemic control
In this article the second in my series on GLP-1 drugs (see the first one here) I explore the science and clinical journey that brought these agents from niche treatments to global disruptors
D., Flatt P
Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
Patients managing chronic conditions like diabetes depend on this medication to protect them from blood sugar-related issues
